Prohibits the knowing sale of xylazine above a certain weight to persons under the age of 21 and without proof of the intended use for institutional, veterinary, or scientific purposes.

This bill makes it illegal to sell xylazine, a drug often used in veterinary medicine, to anyone under the age of 21 unless they can prove it will be used for institutional, veterinary, or scientific reasons. The bill aims to restrict access to this substance to prevent misuse by younger individuals. It specifically targets sales above a certain weight to ensure that only appropriate users can obtain it.

Supporters of the bill argue that it is a necessary step to protect young people from potential harm associated with xylazine misuse. By restricting sales and ensuring that the substance is used only for legitimate purposes, this legislation promotes public health and safety. Advocates believe that this measure will help prevent the drug from being misused and will contribute to a safer community.

Critics of the bill may argue that it unnecessarily restricts access to xylazine for legitimate users, such as researchers and veterinarians, who may need it for their work. They could claim that the age restriction could hinder scientific progress and veterinary care, as it limits the ability of responsible professionals to obtain the substance. Additionally, some may view this as an overreach of government regulation into personal and professional use.